Iovance Biotherapeutics, Inc. (IOVA)
8.28
+0.11
(+1.35%)
USD |
NASDAQ |
Sep 01, 16:00
8.26
-0.02
(-0.24%)
After-Hours: 17:23
Iovance Biotherapeutics Total Long Term Debt (Quarterly) : 43.33M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 43.33M |
| March 31, 2026 | 44.88M |
| December 31, 2025 | 45.40M |
| September 30, 2025 | 46.21M |
| June 30, 2025 | 46.10M |
| March 31, 2025 | 45.22M |
| December 31, 2024 | 45.36M |
| September 30, 2024 | 67.39M |
| June 30, 2024 | 70.25M |
| March 31, 2024 | 73.29M |
| December 31, 2023 | 68.08M |
| September 30, 2023 | 69.01M |
| June 30, 2023 | 69.84M |
| March 31, 2023 | 70.61M |
| December 31, 2022 | 72.86M |
| September 30, 2022 | 72.94M |
| June 30, 2022 | 74.00M |
| March 31, 2022 | 72.18M |
| December 31, 2021 | 66.47M |
| September 30, 2021 | 65.73M |
| June 30, 2021 | 47.84M |
| March 31, 2021 | 48.08M |
| December 31, 2020 | 45.38M |
| September 30, 2020 | 3.711M |
| June 30, 2020 | 2.001M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.088M |
| December 31, 2019 | 4.248M |
| September 30, 2019 | 6.017M |
| June 30, 2019 | 4.613M |
| March 31, 2019 | 4.38M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Amgen, Inc. | 57.30B |
| Halozyme Therapeutics, Inc. | 2.147B |
| Neurocrine Biosciences, Inc. | 401.80M |
| AVITA Medical, Inc. | 48.48M |
| Editas Medicine, Inc. | 64.74M |